CTSB and neoplasm: This study successfully demonstrated the development of a novel peptide-drug conjugate nanoparticle, (Ac)FRRF-DTX (5), which undergoes tumor-selective nanoconversion mediated by cathepsin B, resulting in the formation of the paclitaxel mimic PTXm (3).